The University of Chicago Header Logo

Connection

Fuad Baroody to Omalizumab

This is a "connection" page, showing publications Fuad Baroody has written about Omalizumab.
Connection Strength

0.024
  1. A randomized, double-blind, placebo-controlled trial of anti-IgE for chronic rhinosinusitis. Rhinology. 2010 09; 48(3):318-24.
    View in: PubMed
    Score: 0.024
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.